E(c(RGDfK))2

Send Inquiry
E(c(RGDfK))2
Details
•CAS Number: 250612-47-6
•Synonyms: E[c(RGDfK)]₂; E[c(RGDfK)]c(RGDfK); Dimeric cyclic RGD peptide; Integrin αvβ3 targeting dimer
•Amino Acid Sequence: Two cyclo(-Arg-Gly-Asp-D-Phe-Lys-) cyclic peptides linked through the side chain of a glutamic acid (Glu) residue
•Peptide Length: 5 amino acids per ring, 10 amino acids total + 1 glutamic acid linker (head-to-tail cyclized, containing D-Phe)
•Purity (HPLC): ≥95%
Related Documents
•Certificate of Analysis (COA)
•Mass Spectrometry (MS) Report
•HPLC Purity Report
•Peptide Solubility and Storage Guide
Category
Drug Delivery Peptides
Share to
Description

Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of e(c(rgdfk))2 in China, also supports custom service. Welcome to wholesale bulk high quality e(c(rgdfk))2 from our factory. Contact us for more details.

 

Description E(c(RGDfK))₂ is a dimeric cyclic RGD peptide formed by two c(RGDfK) cyclic peptides linked through the side chain of a glutamic acid (Glu) residue, CAS number 250612-47-6. Each c(RGDfK) unit is cyclo(-Arg-Gly-Asp-D-Phe-Lys-), cyclized via a head-to-tail amide bond, where the introduction of D-phenylalanine (D-Phe) improves the conformational stability and integrin αvβ3 binding affinity of the peptide. The two c(RGDfK) rings are connected through amide bonds formed between the γ-carboxyl group of the glutamic acid side chain and the ε-amino group of the Lys side chain in each ring, constructing a bivalent ligand structure. Compared to monovalent c(RGDfK), the dimeric structure can simultaneously bind two binding sites of integrin αvβ3, significantly enhancing binding affinity and tumor targeting efficiency. Integrin αvβ3 is highly expressed on tumor neovascular endothelial cells and various tumor cell surfaces, and E(c(RGDfK))₂ can specifically target these cells for tumor imaging (SPECT/PET), targeted drug delivery, and anti-angiogenic therapy research. This dimer shows enhanced uptake in human ovarian cancer OVCAR-3 xenograft tumors.
Molecular formula C₅₉H₈₇N₁₉O₁₆
Molecular weight (Da) 1318.46
Structure type Dimeric cyclic peptide (two c(RGDfK) linked via glutamic acid side chain, head-to-tail cyclized, containing D-Phe)
Solubility Freely soluble in water, PBS, DMSO
Storage Condition Powder at -20°C, dry and protected from light

 

Product Basic Information Table

 

Product Standard English Name Product Abbreviation / Alias Function Tags (comma-separated) Core Structure Molecular Formula Exact Mass (Da) Average MW (Da) Salt Form Length (aa)
E(c(RGDfK))2 Dimeric cyclic RGDfK peptide; bivalent integrin-targeting peptide Integrin antagonist, bivalent targeting peptide, tumor targeting, anti-angiogenesis Bivalent ligand formed by linking two cyclic RGDfK pentapeptides via a glutamic acid (E) scaffold; two cyclic RGDfK units can simultaneously bind integrin αvβ₃, with significantly higher binding affinity and specificity than monovalent cyclic peptides, greatly enhancing tumor targeting and anti-angiogenic activity C₅₇H₈₇N₁₉O₁₆ 1254.66 ~1255.9 Acetate 11

 

Physicochemical Solubility & Storage Parameters

 

Product Code Appearance Long-term Storage Short-term Storage Solution Stability Solid Powder Stability
PEP-ERGD2 White powder Store at -20°C, sealed, dry and protected from light. Aliquot for storage. Stable for 1 month at 2–8°C in sealed dry condition; stable for shipping at ambient temperature. Stable for 7 days at 4°C. Soluble in water, dilute acetic acid and PBS. Cyclic structure significantly improves protease resistance and broad pH stability; cyclic peptide bond prone to hydrolysis under extreme strong acid/base. Stable for 2 years at -20°C, dry and protected from light.

Functional Description

 

Product Code Frontend Short Summary (for search list display) Detailed Biological Function Description Applicable Research Areas (comma-separated) Targets / Pathways
PEP-ERGD2 Bivalent cyclic RGDfK peptide with enhanced integrin affinity for tumor targeting E(c(RGDfK))2 is a bivalent cyclic RGD targeting peptide with two cyclic RGDfK units linked via a glutamic acid scaffold. The two units simultaneously bind two binding sites of integrin αvβ₃, increasing binding affinity by tens of folds compared to monovalent peptides. It mediates targeted enrichment of chemotherapeutics, imaging agents and nanoparticles in tumor vasculature and cells. Tumor targeted therapy, anti-angiogenic drugs, tumor molecular imaging, nanocarrier targeting modification, integrin biology Integrin αvβ₃; bivalent cooperative binding; receptor-mediated endocytosis

 

 

 

 

Hot Tags: e(c(rgdfk))2, China e(c(rgdfk))2 manufacturers, suppliers, factory, 191936-91-1, 395069-92-8, CAS 997 20 6, HIV 1 Tat Protein Peptide 47 57 , Tetralysine, therapeutic and pharmaceutical peptides

Send Inquiry